Phase II trial of carbetimer in metastatic melanoma.
A phase II study of the synthetic polyelectrolyte Carbetimer 6500 mg/m2 i.v. daily for five days every 21-day cycle was conducted in patients with metastatic melanoma. No responses were seen in 18 evaluable patients. Two patients had stable disease for five months. Toxicity was generally manageable and included mild hyperphosphatemia, mild proteinuria, fatigue, pain at the injection site, and nausea. Carbetimer is inactive in metastatic melanoma at this dose and schedule.
Quan
W D
WD
USC/Norris Comprehensive Cancer Center, Los Angeles.
Mitchell
M S
MS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D011108:Polymers / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011108:Polymers; C022084:carboxyimamidate